Efficacy and safety of rucaparib maintenance treatment in patients from ARIEL3 with platinum-sensitive, recurrent ovarian carcinoma not associated with homologous recombination deficiency
Authors
Coleman, R. L.Oza, A. M.
Lorusso, D.
Aghajanian, C.
Oaknin, A.
Dean, A.
Colombo, N.
Weberpals, J. I.
Clamp, Andrew R
Scambia, G.
Leary, A.
Holloway, R. W.
Gancedo, M. A.
Fong, P. C. C.
Goh, J. C.
O'Malley, D. M.
Goble, S. M.
Maloney, L.
Ledermann, J. A.
Affiliation
U.S. Oncology Research, The Woodlands, TXIssue Date
2022
Metadata
Show full item recordCitation
Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. Efficacy and safety of rucaparib maintenance treatment in patients from ARIEL3 with platinum-sensitive, recurrent ovarian carcinoma not associated with homologous recombination deficiency. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680301600.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2022.40.16_suppl.5544Additional Links
https://dx.doi.org/10.1200/JCO.2022.40.16_suppl.5544Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2022.40.16_suppl.5544